WO2007052794A1 - オルト置換アニリン誘導体及び抗酸化薬 - Google Patents
オルト置換アニリン誘導体及び抗酸化薬 Download PDFInfo
- Publication number
- WO2007052794A1 WO2007052794A1 PCT/JP2006/322111 JP2006322111W WO2007052794A1 WO 2007052794 A1 WO2007052794 A1 WO 2007052794A1 JP 2006322111 W JP2006322111 W JP 2006322111W WO 2007052794 A1 WO2007052794 A1 WO 2007052794A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- unsubstituted
- formula
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Definitions
- the present invention relates to a novel ortho-substituted aniline derivative and an anti-acid glaze containing the compound as an active ingredient.
- Patent Document 1 A compound represented by the formula is known (see Patent Document 1).
- the blood concentration after administration is low and it does not necessarily have satisfactory transferability, there has been a problem that it does not have sufficient therapeutic activity as an orally administered drug.
- Patent Document 1 International Publication No. 2004/092153 Pamphlet
- the present inventors have found that the reason why the efficacy of an existing antioxidant is not sufficient by oral administration is that the drug does not reach the target site or deactivates the activity before reaching the target site. I thought so. Therefore, it provides an anti-oxidant with better organ transferability, especially high blood transfer after administration, even if it passes through the blood-brain barrier or blood-retinal barrier, or immediately after oral administration. The task is to do.
- a 1 or 2.
- R ° represents an unsubstituted or substituted amino group.
- I ⁇ to R 4 each independently represents a hydrogen atom or an alkyl group.
- E represents an unsubstituted or substituted alkylene chain.
- D represents a single bond, an oxygen atom, an unsubstituted or substituted nitrogen atom, a sulfur atom, a sulfiel group, a sulfol group, a carbo ol group, a carboamino group, or an amino carbo ol group.
- A represents an unsubstituted or substituted aromatic hydrocarbon group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted aralkyl group or an unsubstituted or substituted heteroaralkyl group. . ⁇ Or a salt thereof is provided.
- the present invention relates to an anti-oxidant agent characterized by containing, as an active ingredient, at least one selected from the compound represented by the formula (1) and the group power that also has a salt power. I will provide a.
- the compound represented by the formula (1) or a salt thereof according to the present invention includes arteriosclerosis and myocardial infarction.
- the antioxidant of the present invention is a retinal acidosis disorder inhibitor, a lipoxygenase inhibitor, a 20-HETE synthase inhibitor, a renal disease, a cerebrovascular or cardiovascular disease therapeutic agent and a cerebral infarction therapeutic agent with few side effects. It may be useful as well.
- the compound represented by the formula (1) represents an unsubstituted or substituted amino group, and is preferably an unsubstituted amino group.
- substituents include: an acyl group such as formyl group, acetyl group or benzoyl group; methoxycarbonyl group, ethoxycarbonyl group, n propoxycarbonyl group, isopropoxycarbol group, n butoxy Alkoxy group such as carbo group, s butoxy carboxy group, isobutoxy carbo ol group or t butoxy carbo ol group; methyl group, ethyl group, n-propyl group, isopropyl group, n butyl Group, s butyl group, isobutyl group, t butyl group, n pentyl group or n xyl group, etc.
- an acyl group such as formyl group, acetyl group or benzoyl group
- Aromatic hydrocarbon group such as benzyl group, 1-phenylethyl, 2-phenyl-ruethyl, 1-methylnaphthyl, 2-methylnaphthyl, 1-ethylnaphthyl Group, Ararukiru group such as 2-Echirunafuchiru group; and the like.
- a functional group that can be eliminated or decomposed by being metabolized in vivo is preferable.
- ⁇ represents a hydrogen atom or an alkyl group, and is preferably an alkyl group.
- alkyl groups of I ⁇ R 4 are, the same groups as those obtained by the specific examples of the alkyl group is a substituent of the amino group of R °, preferably a C alkyl group .
- E represents an unsubstituted or substituted alkylene chain, and is preferably an unsubstituted alkylene chain-(CH 2)-(n represents any integer of 16).
- substituent of the alkylene chain include: hydroxyl group; thiol group; fluorine atom, chlorine Halogen atom such as atom, bromine atom, iodine atom; Cyan group; Nitro group; Formyl group; Amino group, Methylamino group, Benzylamino group, Alino group, Dimethylamino group, Jetylamino group
- Unsubstituted or substituted amino groups such as phenylethylamino group; methyl group, ethyl group, n-propyl group, isopropyl group, n butyl group, s butyl group, isobutyl group, t butyl group, n pentyl group, n —Alkyl groups such as hexyl group; alkenyl groups such as bur group and allyl group; alkynyl groups such as ethynyl group, 1 propyl group and propargyl group; methoxy group, ethoxy group, n-propoxy group, Alkoxy groups such as isopropoxy group, n-butoxy group, s-butoxy group, isobutoxy group and t -butoxy group; alkyloxy groups such as vinyloxy group and aralkyloxy group; alkyl groups such as ethuroxy group and propargyloxy group -Luoxy group; ary
- D represents a single bond, an oxygen atom, an unsubstituted or substituted nitrogen atom, a sulfur atom, a sulfur group, a sulfol group, a carbole group, a carboamino group, or an aminocarbole group. Represents.
- A represents an unsubstituted or substituted aromatic hydrocarbon group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted aralkyl group, or an unsubstituted or substituted heteroaralkyl. Represents a group.
- aromatic hydrocarbon group of A include specific examples of the substituent of the alkylene chain of E. Some of them are the same.
- the heterocyclic group of A is not particularly limited as long as it contains at least one hetero atom such as an oxygen atom, a nitrogen atom or a sulfur atom in the ring.
- Specific examples include furan 2-yl. Group, furan-3-yl group, thiophene-2-yl group, thiophene-3-yl group, pyrrole-2-yl group, pyrrole-3-yl group, oxazole-2-yl group, oxazole-4-yl group Oxazole-5-yl group, thiazole-2-yl group, thiazole-4-yl group, thiazole-5-yl group, isoxazole-3-yl group, isoxazole-4-yl group, iso Oxazol-5-yl group, isothiazole-3-yl group, isothiazo 4-yl group, isothiazol-5-yl group, imidazol-2-yl group, imidazol 4-yl group, imida
- aralkyl group of A examples include a benzyl group and a phenethyl group.
- heteroaralkyl group of A examples include a 3 cherylmethyl group, a 2 pyridylmethyl group, a 3 pyridylmethyl group, and a 2 pyrimidylmethyl group.
- Examples of the substituent of the aromatic hydrocarbon group, heterocyclic group, aralkyl group and heteroaralkyl group of A include those similar to some of the specific examples of the substituent of the alkylene chain of E. It is done.
- R 5 represents a hydroxyl group, a halogen atom, or an organic group having no substituent or a substituent.
- Specific examples of the halogen atom for R 5 is a fluorine atom, a chlorine atom, a bromine atom and an iodine MotoHara children.
- the organic group in R 5 represents a general functional group containing a carbon atom, and specific examples thereof include a cyan group, an alkyl group, and a formyl group similar to some of the specific examples of the substituent of E.
- R 5 together when e ⁇ i is 2 or more, which will be described later are the same or different, Ru. Also, R 5 can be joined together to form a ring.
- the nitrogen atom in (A-1), (A-3), (A-4) and (A-5) can be directly bonded to D, and when not directly bonded to D, Hydrogen atoms or R 5 shall be bonded within the chemically acceptable range.
- A is a specific example in which groups represented by the formulas (A-1) to (A-5) are preferable.
- Compound (1) can be produced, for example, by the method shown below.
- compound (2) the -tro group of the compound represented by the formula (2) (hereinafter sometimes referred to as “compound (2)”)
- compound (11) the compound represented by the formula (11), which is the compound of the present invention (hereinafter referred to as “compound (11)”), is either hydrogenated in the presence of a hydrogenation catalyst or reduced with a reducing agent. Can be obtained).
- the hydrogenation catalyst used in the hydrogenation reaction of compound (2) is not particularly limited, and examples thereof include conventionally known hydrogenation catalysts such as palladium carbon, palladium hydroxide, platinum dioxide, Raney nickel.
- This hydrogenation reaction can be carried out in a suitable solvent.
- the solvent to be used is not particularly limited as long as it is an inert solvent for the reaction.
- alcohols such as methanol and ethanol, ethers such as jetyl ether, tetrahydrofuran (hereinafter sometimes referred to as “THF”), and 1,4 dioxane
- carbonization such as benzene, toluene, xylene, and cyclohexane Hydrogen
- Amides such as N, N dimethylformamide (hereinafter sometimes referred to as “DMF”);
- Organic acids such as formic acid and acetic acid; Esters such as ethyl acetate; and two or more of these A mixed solvent;
- a method of using a reducing agent for the compound (2) for example, a method of reducing with hydrochloric acid and stannous chloride in an alcohol solvent such as methanol and ethanol; a ketone such as acetone and methyl ethyl ketone Reduction using acetic acid and iron in a mixed solvent of water and water; ammonium chloride, ammonium acetate, ammonium formate or acetic acid and zinc in a mixed solvent of alcohol or alcohol and water And the like.
- an alcohol solvent such as methanol and ethanol
- a ketone such as acetone and methyl ethyl ketone Reduction using acetic acid and iron in a mixed solvent of water and water
- ammonium chloride, ammonium acetate, ammonium formate or acetic acid and zinc in a mixed solvent of alcohol or alcohol and water And the like.
- reaction temperature is in the temperature range up to the boiling point of the solvent that also uses 0 ° C force.
- the compound (1) of the present compound (11) can be converted to the compound of the present invention (1) by derivatization to the amino group by a conventionally known method such as alkylation of aryl.
- the production intermediate (2) can be produced by a general reaction as follows.
- the compound (4) can be obtained by formylation by allowing an oxidant to act on the compound represented by the formula (3).
- this reaction is carried out by dissolving amines such as triethylamine, pyridine, and DBU in a solvent solution of compound (3) such as t-butanol; sodium hydrogen carbonate, sodium carbonate, potassium carbonate, After adding a base such as sodium hydroxide hydroxide at room temperature, a saturated hydrocarbon such as n-hexane and water are added to the mixture, and an oxidizing agent such as potassium permanganate, And boric acid is added, and the whole volume is stirred at -20 ° C to + 50 ° C, preferably -10 ° C to + 10 ° C.
- compound (4) is subjected to, for example, a alkelloi reaction by a Wittig reaction, followed by extension of an alkylene chain by a general reduction reaction (a compound ( 2).
- D is an oxygen atom, an unsubstituted or substituted nitrogen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, or a carbonylamino group
- the compound (4) is converted into a hydroxyl group using a reducing agent, If necessary, a leaving group can be introduced to obtain the compound (2) by a general coupling reaction or the like.
- the compound (4) is converted into a carboxylic acid using a general oxidizing agent and is derivatized into an acid halide, followed by a general coupling reaction or the like.
- Compound (2) can be obtained.
- the structure of the obtained compound can be identified and confirmed by measuring IR, NMR, MS spectrum and the like.
- Compound (1) includes compounds in which optical isomers and tautomers exist. All of these are within the scope of the present invention.
- the salt of the compound (1) is not particularly limited as long as it is a salt of the compound represented by the formula (1), but a pharmacologically acceptable salt is preferable.
- Strong salts include salts of inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid; organics such as acetic acid, propionic acid, lactic acid, succinic acid, tartaric acid, citrate, benzoic acid, salicylic acid, nicotinic acid and heptagluconic acid Acid salts; These can be easily produced by ordinary synthetic chemical techniques.
- the anti-acid drug of the present invention comprises at least one selected from the group consisting of the compound represented by the formula (1) and a pharmacologically acceptable salt thereof (hereinafter referred to as “the compound of the present invention”). It is contained as an effective component.
- the compound of the present invention has an excellent antioxidant action, it is possible to prevent oxidative denaturation of low density lipoprotein (hereinafter sometimes referred to as "LDL" t). It can prevent the development and progression of arteriosclerotic lesions and can be applied to therapeutic drugs for arteriosclerosis. It is also useful as a therapeutic agent for various diseases based on oxidation, such as senile dementia disease, heart disease, cancer, diabetes, gastrointestinal disease, burns, eye disease, and kidney disease. Furthermore, in ischemic organ diseases such as stroke and myocardial infarction, various active oxygens are generated during blood reperfusion at the ischemic site, and tissue damage is exacerbated by cell membrane destruction due to lipid peroxidation. Can remove various active oxygen and peroxyphospholipid by its antioxidant activity, prevent tissue damage of ischemic lesions, and can be applied as a therapeutic agent for ischemic organ damage.
- LDL low density lipoprotein
- some of the compounds of the present invention have a lipoxygenase inhibitory action and a 20-HETE synthase inhibitory action.
- lipoxygenase inhibitory action By inhibiting the action of lipoxygenase, arachidonic acid is converted to hydroperoxyeicosatetraenoic acid ( Also included are compounds that can inhibit the conversion to HPETE) and inhibit the production of 20-HETE by inhibiting 20-HET E synthase.
- the compounds of the present invention also include compounds that have a small dopamine release inhibitory action and a low possibility of accompanying side effects such as Parkinson-like.
- the compound of the present invention comprises (a) a disease caused by retinal oxidative disorder, b) diabetes, c) hypertension D) arteriosclerosis, e) anemia, 1) leukemia, g) connective tissue diseases such as systemic lupus erythematosus and scleroderma, h) Tays-Sacks disease and folk toe peel meyer (Vogt) — Retinal vascular disorders and inflammatory and degenerative lesions caused by systemic diseases such as inborn errors of metabolism such as Spielmeyer's disease, 0 (retinopathy of prematurity, retinal vein occlusion, retinal artery occlusion, periretinitis, etc.) ) Retinal vascular disorders, j) retinal inflammation or degeneration resulting from retinal detachment or trauma, k) age-related retinal degenerative diseases such as age-related macular degeneration, 1) congenital retinal degenerative diseases, etc. It can be used for the
- the therapeutically effective amount of the compound of the present invention varies depending on the individual and the condition of the disease to be treated.
- the therapeutically effective daily dose can be 0.114 mg to 14.3 mgZ day of the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof per 1 kg body weight, From 0.7 mg per kg: LOmgZ days, more preferably from 1.4 mg to 7.2 mgZ days per kg body weight.
- the dose range of the compound of formula (1) or a pharmaceutically acceptable salt thereof is 10 mg to l.0 g per day, preferably 1 to 50 mg to 700 mg, More preferably, doses outside this range may be used depending on the condition of force treatment of 1 mg to 100 mg to 500 mg.
- the antioxidant of the present invention in addition to a conventional pharmaceutical carrier or excipient, other drugs, adjuvants and the like do not react with other components. It can be set as the containing composition.
- a composition may contain 1 to 99% by weight of the active ingredient and 99 to 1% by weight of a suitable pharmaceutical carrier or excipient, depending on the mode of administration, and preferably contains the active ingredient. 5 to 75% by weight, and the balance can be used as a suitable pharmaceutical carrier or excipient.
- any conventionally used excipient such as pharmaceutical maltol, lactose, starch, gelatinized starch, magnesium stearate Saccharin sodium, talc, cellulose ether derivatives, glucose, gelatin, sucrose, kennate, propyl gallate and the like.
- oral antioxidants for example, lactose, sucrose, dicalcium phosphate and the like as diluents, and disintegrants, for example, croscarmellose sodium or its derivatives, etc. as binders
- magnesium stearate or the like can be used as a lubricant, for example, starch, gum arabic gum, polybulurpyrrolidone, gelatin, cellulose ether derivatives, or the like.
- the antioxidant of the present invention can be administered in any manner as a medicament for the above diseases.
- the form can be administered orally, nasally, parenterally, topically, transdermally or rectally, and the form can also be a solid, semi-solid, lyophilized powder or liquid dosage form such as a tablet, suppository Pills, soft and hard capsules, powders, solutions, injections, suspensions, aerosols, sustained-release preparations, etc., and can be formulated accurately and easily administered. Appropriate dosage forms can be obtained.
- Such formulations can be prepared using conventional methods, such as Remington's Pharmaceutical Sciences, 18th, McNabricing, Power Nno, N., Easton, Penn Publishing Company, Easton, Pennsylvania) according to the description taught in 1990.
- the injection includes sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- aqueous solution and suspension diluent include distilled water for injection and physiological saline.
- water-insoluble solutions and suspension diluents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate (trade name), and the like.
- These compositions may further contain additives such as tonicity agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers (eg, extra-loose), soluble additives or solubilizers. Include it. These can be used, for example, by filtration through a bacteria-retaining filter, producing a solid composition of a disinfectant and dissolving it in sterile water or a sterile solvent for injection before use.
- a carrier that gradually dissolves in the body as the carrier for example, polyoxyethylene glycol or polyethylene glycol (hereinafter sometimes referred to as "PEG").
- PEG1000 96%) or PEG4000 (4%) is used, and 0.5 to 50% by weight of the compound of the formula (1) or a pharmaceutically acceptable salt thereof is dispersed in a strong carrier. We can mention them.
- antioxidant of the present invention When the antioxidant of the present invention is used as a liquid, water, saline, dextrose aqueous solution, glycerol, ethanol or the like is used as a carrier, and the compound of formula (1) or a pharmaceutically acceptable salt thereof is used as a strong carrier.
- a solution or suspension is preferably used by performing treatment such as dissolving or dispersing any pharmaceutical adjuvant with 0.5 to 50% by weight of an acceptable salt.
- the compound of the present invention can be suitably used particularly as a retinal photooxidation disorder inhibitor.
- the administration mode, dosage form, and dosage can be the same manner, form, and dosage as the above antioxidants, and include the same formulation components, carriers, adjuvants, etc. as the above antioxidants.
- One or more excipients, disintegrants, binders, and other retinal oxidative disorder inhibitors that do not react with the active ingredient may be added as appropriate.
- a component having a medicinal effect may be contained as appropriate.
- eye drops and eye ointments can be used.
- the retinal photoacidotoxicity suppression plan of the present invention is used as an eye drop
- one or more of the compounds of the present invention are added to a commonly used base solvent to form an aqueous solution or suspension.
- the pH can be adjusted to 4-10, preferably 5-9. Since the eye drops are sterile products, sterilization, which is preferable to sterilize, can be performed at any stage of the manufacturing process.
- the concentration of the compound of the present invention in the eye drop is 0.001 to 3% (W / V), preferably 0.
- the dosage can be 1 to 4 times a day depending on various conditions such as the degree of symptoms and the constitution of the patient.
- the above dose is a guide and can be administered beyond this range.
- the above eye drops include buffers, isotonic agents, preservatives within a range not reacting with the compound of the present invention.
- additives such as pH adjusters, thickeners, chelating agents and solubilizers may be added as appropriate.
- Examples of the buffering agent include a citrate buffer, a tartaric acid buffer, an acetate buffer, an amino acid, and the like.
- Examples of the isotonic agent include sorbitol, dalcose. And saccharides such as mannitol, polyhydric alcohols such as glycerin, polyethylene glycol and propylene glycol, and salts such as sodium chloride sodium.
- Examples of preservatives include paraoxy such as methyl noroxybenzoate and ethyl oxybenzoate. Examples thereof include benzoic acid esters, benzyl alcohol, phenethyl alcohol, sorbic acid or a salt thereof, and examples of the pH adjuster include phosphoric acid and sodium hydroxide.
- Examples of the thickening agent include hydroxyethyl cellulose, hydroxypropenoresenorelose, methinoresenorelose, hydroxypropinoresmethinoresoleose, carboxymethylcellulose and salts thereof, and the chelating agent.
- Examples of the solubilizer include sodium edetate, sodium citrate, and condensed sodium phosphate.
- Examples of the solubilizer include ethanol and polyoxyethylene hydrogenated castor oil.
- the retinal photoacidosis disorder inhibitor of the present invention is used as an eye ointment
- one or more of the compounds of the present invention are usually used in eye ointment bases such as purified lanolin and white petrolatum. It can be mixed with macrogol, plastibase, liquid paraffin, etc. and is preferably sterilized to produce a sterile product.
- the concentration of the compound of the present invention in the eye ointment is 0.001 to 3% (W / W), preferably 0.
- the dosage can be 1 to 4 times a day depending on various conditions such as the degree of symptoms and the constitution of the patient.
- the above dose is a guideline and can be administered beyond this range.
- the retinal photooxidation disorder inhibitor of the present invention has an excellent antioxidant action, it is effective for the prevention and treatment of degenerative diseases of the retina accompanying aging such as age-related macular degeneration. is there.
- Step 1 Production of 2, 2, 6, 7-tetramethyl-1,5-trodihydrobenzofuran-1,4 aldehyde
- Step 2 2, 2, 6, 7-tetramethyl-4-stilyl 5-of trodihydrobenzofuran
- Example 2 4- (5-Amino-2,2,6,7-tetramethyldihydrobenzofuran 4-ylmethyl) 1-[(4-imidazole-1-yl) phenylmethyl] piperazine Step 1: 4— (5-—Toro-1,2,6,7-tetramethyldihydrobenzofuran 4-ylmethyl) 1 — [(4-imidazole-1-yl) phenylmethyl]] pi Manufacture of perazine
- Step 2 Production of 4- (5-amino-2,2,6,7-tetramethyldihydrobenzofuran-4-ylmethyl) 1-[(4-imidazole-1-yl) phenylmethyl] piperazine
- Step 2 Production of 5- (4- (5-amino-5,2,6,7-tetramethyldihydrobenzofuran-4-ylmethyl) aminophenyl) pyrazole
- Step 1 5— (4— (5-Toro 2, 2, 6, 7-tetramethyldihydrobenzofuran 4-ylmethyl) aminophenol) 1— (Tetrahydropyran-2-yl) Production of pyrazole
- the reaction solution was cooled, washed with 19 ml of 3N aqueous ammonia, and then washed with water until the pH of the organic layer became 7.
- the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Step 2 5— (4— (5-trough 2, 2, 6, 7-tetramethyldihydrobenzofuran-4-ylmethyl) N-acetylaminophenol) 1 1- (tetrahydropyran 2—Ill) Manufacture of pyrazole
- Step 3 Preparation of 5— (4— (5 amino-2,2,6,7-tetramethyldihydrobenzofuran-4-ylmethyl) -N-acetylaminophenol) pyrazole
- Step 1 Production of 2, 2, 6, 7-tetramethyl-1,5-trodihydrobenzofuran 2-ylmethyl methanesulfonate
- Step 2 Production of 1,4 (5-trough 2, 2, 6, 7-tetramethyldihydrobenzofuran-4-ylmethoxy) acetophenone
- Step 3 5— (4— (5-trough 2, 2, 6, 7—tetramethyldihydrobenzofuran 4 L) Production of pyrazole
- Step 4 Preparation of 5- (4- (5-amino-1,2,6,7-tetramethyldihydrobenzofuran-4-ylmethoxy) furyl) pyrazole
- 1N Hydrochloric acid was added to the residue and the mixture was washed 3 times with black mouth form.
- 1N sodium hydroxide was added to the aqueous layer, extracted with black mouth form, and washed with saturated brine.
- the obtained organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to obtain 0.30 g of the desired product.
- Step 1 1-tert Butoxycarbo-biperidine-4-yl Methanesulfonate production
- Step 2 1— (1—tert-Butoxycarborubiperidine-4-yl) —3-Ferrubirazole production
- the organic layer was washed 3 times with water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- Step 4 1— (1— (5-tro-1,2,6,7-tetramethyldihydrobenzofuran-4-ylmethyl) piperidine 4-yl)-3-phenol-birazole Manufacturing
- Step 5 1— (1— (5 amino 1, 2, 6, 7, 7-tetramethyldihydrobenzofuran 4-ylmethyl) piperidine 4-yl)-Preparation of 3-phenol-rubirazole
- ND 2 ° ' 8 1.5852 means that the refractive index at 20. 8 ° C is 1.5852 (the same applies to others) o
- Me methyl group
- Et ethyl group
- iPr isopropyl group
- nBu normal butyl group
- tBu tertiary butyl group
- Ph phenol group
- Ac acetyl group
- Bn benzyl group
- the organ used was a retina stored at ⁇ 80 ° C. after separation of porcine eye force. At the time of use, 5 times the amount of phosphate buffered saline (pH 7.4) is added, and the micro homogenizer (PH).
- Malondialdehyde produced by the decomposition of peroxyphospholipid was measured by the thiobarbituric acid method.
- the measured force also represents the 50% inhibitory concentration (hereinafter sometimes referred to as “IC”) of the compound of the present invention.
- the compound of the present invention has an in vitro effect of inhibiting peracid lipid formation.
- Tissue migration of the compounds of the present invention was evaluated by measuring ex vivo lipid peroxide production inhibitory action.
- the compound of the present invention was dissolved in DMSO (final concentration 20%) and dissolved or suspended in 0.1N hydrochloric acid saline or 1% polyethylene hardened castor oil (NIKOL HCO 60, manufactured by Nikko Chemical Co., Ltd.).
- This solution was administered orally at a rate of 30 mgZkg to 3 male SD rats (Japan SLC, 6 weeks old) or non-fasted SD male rats (Japan SLC, 6 weeks old) fasted for 24 hours per group. did.
- One hour after administration the brain and eyeball were removed after anesthesia.
- the amount of peroxyphospholipid in each tissue homogenate was measured by the method described in the above section (In vitro lipid peroxide production inhibitory action evaluation test).
- the inhibition rate of each compound of the present invention in each tissue was determined from the amount of lipid peroxide produced in the control group (20% DMSO 0.1N hydrochloric acid physiological saline Zl% polyethylene hydrogenated castor oil group) and the compound administered group of the present invention. It was. The results are shown in the table below. From the table below, it has been clarified that the compound of the present invention also has the ability to migrate to the brain, which has a high tissue migration ability.
- the compound of the present invention was dissolved in DMSO (final concentration 20%) and dissolved or suspended in 0.1N hydrochloric acid saline or 1% polyethylene hardened castor oil (NIKOL HCO 60, manufactured by Nikko Chemical Co., Ltd.). This solution was orally administered at a rate of 30 mgZkg to 3 SD male rats (Japan SLC, 6 weeks old) per group.
- NIKOL HCO 60 polyethylene hardened castor oil
- the compound represented by the above formula (1) of the present invention or a salt thereof is used to treat ischemic organ disorders such as arteriosclerosis, myocardial infarction, cerebral infarction, etc., or diseases caused by oxidative cell disorders such as renal diseases. It has effective antioxidant activity. Therefore, it is possible to effectively suppress retinal damage caused by acid due to the influence of light or the like, and to provide an excellent antioxidant containing the ortho-substituted phosphine derivative of the present invention.
- the antioxidant of the present invention is a retinal acidosis disorder inhibitor, a lipoxygenase inhibitor, a 20-HETE synthase inhibitor, a renal disease, a cerebrovascular or cardiovascular disease therapeutic agent and a cerebral infarction therapeutic agent with few side effects. It is also useful.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006309576A AU2006309576B2 (en) | 2005-11-04 | 2006-11-06 | Ortho-substituted aniline derivative and antioxidant drug |
EP06823024A EP1944024A1 (en) | 2005-11-04 | 2006-11-06 | O-substituted aniline derivative and antioxidant drug |
CA002628014A CA2628014A1 (en) | 2005-11-04 | 2006-11-06 | Ortho-substituted aniline derivative and antioxidant drug |
US12/092,294 US20090275753A1 (en) | 2005-11-04 | 2006-11-06 | Ortho-substituted aniline derivative and antioxidant drug |
JP2007542838A JPWO2007052794A1 (ja) | 2005-11-04 | 2006-11-06 | オルト置換アニリン誘導体及び抗酸化薬 |
NO20082422A NO20082422L (no) | 2005-11-04 | 2008-05-29 | Ortho-substituert anilinderivat og antioksidant-legemiddel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005321612 | 2005-11-04 | ||
JP2005-321612 | 2005-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007052794A1 true WO2007052794A1 (ja) | 2007-05-10 |
Family
ID=38005945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/322111 WO2007052794A1 (ja) | 2005-11-04 | 2006-11-06 | オルト置換アニリン誘導体及び抗酸化薬 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090275753A1 (ja) |
EP (1) | EP1944024A1 (ja) |
JP (1) | JPWO2007052794A1 (ja) |
KR (1) | KR20080053950A (ja) |
CN (1) | CN101300243A (ja) |
AU (1) | AU2006309576B2 (ja) |
CA (1) | CA2628014A1 (ja) |
NO (1) | NO20082422L (ja) |
RU (1) | RU2384579C2 (ja) |
WO (1) | WO2007052794A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133701A1 (ja) * | 2008-05-01 | 2009-11-05 | 日本曹達株式会社 | フェニルイミダゾール誘導体並びに網脈絡膜障害治療薬及び/又は予防薬 |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2015002061A1 (ja) | 2013-07-04 | 2015-01-08 | 日本曹達株式会社 | フェニルイミダゾール誘導体、および炎症性疾患などの治療薬若しくは予防薬 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2472794C1 (ru) * | 2011-05-25 | 2013-01-20 | Федеральное государственное образовательное учреждение высшего профессионального образования Астраханский государственный технический университет (ФГОУ ВПО АГТУ) | Новые бициклические производные пирролидинов, обладающие антиоксидантной активностью, и способ их получения |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476777A (en) * | 1965-10-27 | 1969-11-04 | Yamanouchi Pharma Co Ltd | Novel 6-chromanol derivatives and their preparation |
JPH07112980A (ja) * | 1993-08-24 | 1995-05-02 | Ono Pharmaceut Co Ltd | 縮合フェノール誘導体およびその誘導体を有効成分として含有する薬剤 |
WO2004092153A1 (ja) * | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | ジアミン誘導体、製造法及び抗酸化薬 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0640609A1 (en) * | 1993-08-24 | 1995-03-01 | Ono Pharmaceutical Co., Ltd. | Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species |
DE59508773D1 (de) * | 1994-07-22 | 2000-11-09 | Byk Gulden Lomberg Chem Fab | Dihydrobenzofurane |
-
2006
- 2006-11-06 WO PCT/JP2006/322111 patent/WO2007052794A1/ja active Application Filing
- 2006-11-06 EP EP06823024A patent/EP1944024A1/en not_active Withdrawn
- 2006-11-06 US US12/092,294 patent/US20090275753A1/en not_active Abandoned
- 2006-11-06 KR KR1020087010495A patent/KR20080053950A/ko not_active Application Discontinuation
- 2006-11-06 AU AU2006309576A patent/AU2006309576B2/en not_active Ceased
- 2006-11-06 CA CA002628014A patent/CA2628014A1/en not_active Abandoned
- 2006-11-06 RU RU2008121726/04A patent/RU2384579C2/ru not_active IP Right Cessation
- 2006-11-06 JP JP2007542838A patent/JPWO2007052794A1/ja not_active Withdrawn
- 2006-11-06 CN CNA2006800407806A patent/CN101300243A/zh active Pending
-
2008
- 2008-05-29 NO NO20082422A patent/NO20082422L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476777A (en) * | 1965-10-27 | 1969-11-04 | Yamanouchi Pharma Co Ltd | Novel 6-chromanol derivatives and their preparation |
JPH07112980A (ja) * | 1993-08-24 | 1995-05-02 | Ono Pharmaceut Co Ltd | 縮合フェノール誘導体およびその誘導体を有効成分として含有する薬剤 |
WO2004092153A1 (ja) * | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | ジアミン誘導体、製造法及び抗酸化薬 |
Non-Patent Citations (3)
Title |
---|
HAMMOND M.L. ET AL.: "2,3-Dihydro-5-benzofuranols as antioxidant-based inhibitors of leukotriene biosynthesis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 5, 1989, pages 1006 - 1020, XP000673754 * |
HAMMOND M.L. ET AL.: "Antioxidant-based inhibitors of leukotriene biosynthesis. The discovery of 6-[1-[2-(hydroxymethyl)phenyl]-1-propen-3-y]-2,3-dihydro-5-benzofuranol, a potent tropical anti-inflammatory agent", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 3, 1990, pages 908 - 918, XP000673907 * |
OHKAWA S. ET AL.: "5-Aminocoumarans: Dual inhibitors of lipid peroxidation and dopamine release with protective effects against central nervous system trauma and ischemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 1997, pages 559 - 573, XP002979756 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133701A1 (ja) * | 2008-05-01 | 2009-11-05 | 日本曹達株式会社 | フェニルイミダゾール誘導体並びに網脈絡膜障害治療薬及び/又は予防薬 |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2015002061A1 (ja) | 2013-07-04 | 2015-01-08 | 日本曹達株式会社 | フェニルイミダゾール誘導体、および炎症性疾患などの治療薬若しくは予防薬 |
JPWO2015002061A1 (ja) * | 2013-07-04 | 2017-02-23 | 日本曹達株式会社 | フェニルイミダゾール誘導体、および炎症性疾患などの治療薬若しくは予防薬 |
Also Published As
Publication number | Publication date |
---|---|
AU2006309576B2 (en) | 2010-04-15 |
KR20080053950A (ko) | 2008-06-16 |
NO20082422L (no) | 2008-07-24 |
CN101300243A (zh) | 2008-11-05 |
RU2008121726A (ru) | 2009-12-10 |
AU2006309576A1 (en) | 2007-05-10 |
JPWO2007052794A1 (ja) | 2009-04-30 |
CA2628014A1 (en) | 2007-05-10 |
RU2384579C2 (ru) | 2010-03-20 |
US20090275753A1 (en) | 2009-11-05 |
EP1944024A1 (en) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113816948B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
US4355036A (en) | Tricyclic-substituted piperidine antihistamines | |
JP3220266B2 (ja) | アザヘテロサイクリルメチル−クロマン | |
TW202144340A (zh) | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 | |
JP2007016011A (ja) | 抗酸化活性を有する新規な含窒素ヘテロ環化合物、及び該化合物を含有する抗酸化薬 | |
WO2007037534A1 (ja) | 2-へテロアリール置換インドール誘導体 | |
JP4949246B2 (ja) | ベンズイミダゾール化合物 | |
US20090306055A1 (en) | Phenylazole compounds, production process and antioxidants | |
TWI718113B (zh) | 吡啶甲醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
KR20080069208A (ko) | mPGES-1 억제제로서 2-(페닐 또는헤테로사이클릭)-1H-페난트로[9,10-d]이미다졸 | |
JPH0561274B2 (ja) | ||
WO2007122686A1 (ja) | ベンズイミダゾール化合物 | |
WO2007052794A1 (ja) | オルト置換アニリン誘導体及び抗酸化薬 | |
CN114456163B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
EP0529654A1 (en) | Benzopyran derivatives as potassium channel activators and 5-lipoxygenase inhibitors | |
DE3421641A1 (de) | Indolderivate | |
US5691348A (en) | Pyridyl imidazole derivatives and processes for the preparation thereof | |
RU2194049C2 (ru) | Производные тиадиазолил пиридазина, ингибирующие ангиогенез, способ их получения, фармацевтическая композиция и способ ее получения | |
JPH03163074A (ja) | フラン誘導体 | |
JP3588363B2 (ja) | キノキサリンジオン類 | |
TWI439270B (zh) | 苯并咪唑化合物 | |
JPS61100579A (ja) | ピリジン誘導体 | |
CH616425A5 (ja) | ||
US4454143A (en) | Tricyclic antihistamines | |
EP1383761B1 (fr) | Phenyl- et pyridyl-pipéridines avec une activité du tnf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680040780.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007542838 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006309576 Country of ref document: AU Ref document number: 2006823024 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2628014 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1746/KOLNP/2008 Country of ref document: IN Ref document number: 1020087010495 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12092294 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006309576 Country of ref document: AU Date of ref document: 20061106 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008121726 Country of ref document: RU |